CSIMarket
 


Kempharm Inc  (KMPH)
Other Ticker:  
 

Kempharm Inc's Quick Ratio

KMPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




KMPH Quick Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 151.75 % 27.45 % -33.65 % -46.26 % -95.25 %
Y / Y Cash & cash equivalent Change -42.29 % -38.79 % 33.8 % 2566.65 % 2396.73 %
Quick Ratio MRQ 9 11.31 39.24 29 39.27
Overall Ranking # # # # #
Seq. Current Liabilities Change 17.77 % 176.52 % -33.17 % 15.68 % -40.38 %
Seq. Cash & cash equivalent Change -6.28 % -20.28 % -9.58 % -14.57 % -0.6 %



Quick Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 9 above Kempharm Inc average.

Within Major Pharmaceutical Preparations industry Kempharm Inc booked the highest Quick Ratio than Kempharm Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Quick Ratio?
What are KMPH Segments?
See Quick Ratio KMPH on the trailing twelve month basis
Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Kempharm Inc's Current Liabilities $ 8 Millions Visit KMPH's Balance sheet
Kempharm Inc's Cash & cash equivalent $ 76 Millions Visit KMPH's Balance sheet
Source of KMPH's Sales Visit KMPH's Sales by Geography


Cumulative Kempharm Inc's Quick Ratio

KMPH's Quick Ratio for the trailling 12 Months

KMPH Quick Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 151.75 % 27.45 % -33.65 % -46.26 % -95.25 %
Y / Y Cash & cash equivalent TTM Growth -42.29 % -38.79 % 33.8 % 2566.65 % 2396.73 %
Quick Ratio TTM 16.81 25.13 30.96 27 17.13
Total Ranking TTM # 123 # 129 # 96 # 129 # 210
Seq. Current Liabilities TTM Growth 17.77 % 176.52 % -33.17 % 15.68 % -40.38 %
Seq. Cash & cash equivalent TTM Growth -6.28 % -20.28 % -9.58 % -14.57 % -0.6 %


TTM Quick Ratio Comment
On the trailing twelve months basis Due to increase in Current Liabilities in the III. Quarter to $8.43 millions, average cumulative Quick Ratio decreased to 16.81 below the Kempharm Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Quick Ratio than Kempharm Inc. While overall ranking remained unchanged compare to previous quarter at no. 123.

Explain Quick Ratio?
What are KMPH Segments?
See Quick Ratio KMPH on the trailing twelve month basis

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 61
Healthcare Sector # 85
Within the Market # 123


TTM Quick Ratio Statistics
High Average Low
28.38 7.77 0.08
(Mar 31 2022)   (Sep 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Morphic Holding inc   24.39 $ 371.760  Millions$ 15.241  Millions
Infinity Pharmaceuticals Inc   24.17 $ 47.182  Millions$ 1.952  Millions
Diamedica Therapeutics Inc   24.05 $ 36.093  Millions$ 1.501  Millions
Io Biotech Inc   23.92 $ 151.168  Millions$ 6.321  Millions
Pasithea Therapeutics Corp   23.08 $ 42.398  Millions$ 1.837  Millions
Dice Therapeutics Inc   22.86 $ 266.614  Millions$ 11.665  Millions
Anaptysbio inc  22.76 $ 442.966  Millions$ 19.459  Millions
Seres Therapeutics Inc   22.30 $ 233.003  Millions$ 10.449  Millions
Pmv Pharmaceuticals Inc   22.21 $ 258.857  Millions$ 11.656  Millions
Keros Therapeutics Inc   21.63 $ 239.426  Millions$ 11.070  Millions
Ironwood Pharmaceuticals inc   21.17 $ 574.188  Millions$ 27.117  Millions
Cassava Sciences Inc   21.02 $ 174.662  Millions$ 8.308  Millions
Janux Therapeutics Inc   20.74 $ 338.760  Millions$ 16.335  Millions
Eliem Therapeutics Inc   20.68 $ 122.619  Millions$ 5.928  Millions
Day One Biopharmaceuticals Inc   20.49 $ 374.341  Millions$ 18.271  Millions
Ovid Therapeutics Inc   20.48 $ 137.897  Millions$ 6.732  Millions
Forte Biosciences Inc   19.21 $ 44.048  Millions$ 2.293  Millions
Kura Oncology Inc   19.06 $ 427.775  Millions$ 22.441  Millions
Lantern Pharma Inc   18.98 $ 57.827  Millions$ 3.047  Millions
Verve Therapeutics Inc   18.98 $ 550.710  Millions$ 29.018  Millions
Nuvalent Inc   18.50 $ 240.064  Millions$ 12.975  Millions
Minerva Neurosciences Inc   18.31 $ 40.220  Millions$ 2.197  Millions
Agios Pharmaceuticals Inc   18.11 $ 727.680  Millions$ 40.171  Millions
Astria Therapeutics inc   18.10 $ 116.571  Millions$ 6.441  Millions
Olema Pharmaceuticals inc   17.73 $ 222.600  Millions$ 12.552  Millions
Point Biopharma Global Inc   17.55 $ 291.519  Millions$ 16.608  Millions
Generation Bio Co   17.39 $ 301.169  Millions$ 17.318  Millions
Pardes Biosciences Inc   17.38 $ 209.055  Millions$ 12.028  Millions
Annovis Bio inc   17.33 $ 31.987  Millions$ 1.846  Millions
Stoke Therapeutics Inc   17.06 $ 251.655  Millions$ 14.749  Millions

Date modified: 2022-11-12T19:26:45+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RCAT's Profile

Stock Price

RCAT's Financials

Business Description

Fundamentals

Charts & Quotes

RCAT's News

Suppliers

RCAT's Competitors

Customers & Markets

Economic Indicators

RCAT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071